Migraine

Patients using intranasal zavegepant for acute migraines report significant pain relief and improved daily functioning, highlighting its real-world effectiveness.

A recent survey reveals rimegepant's effectiveness for short-term migraine prevention, highlighting user demographics, triggers, and treatment strategies.

Chia-Chun Chiang, MD, associate professor of neurology at Mayo Clinic Rochester, discussed how AI-based ECG and imaging tools can aid in predicting stroke and cardiovascular outcomes in patients with migraine.

Jennifer Robblee, MD, MSc, headache neurologist at the Barrow Neurological Institute, talked about an expert panel that developed a consensus definition for refractory migraine.

Nathaniel M. Schuster, MD, associate clinic director at the UC San Diego, talked about findings from a study of vaporized cannabis in treating patients with acute migraine presented at AHS 2025.

Laura Sebrow, PhD, a post doctoral neuropsychology fellow at North Shore University Hospital, discussed the relationship between patients’ reported cognitive difficulties and measurable cognitive performance during different migraine phases.

Marcela Romero-Reyes, DDS, PhD, FAHS, director of the Brotman Facial Pain Clinic at the University of Maryland, discussed a promising and potentially safer therapeutic approach for managing trigeminal neuropathic pain.

Markted as Brekiya, Amneal Pharmaceuticals’ newly approved therapy offers a self-administered version of dihydroergotamine mesylate for adults with migraine or cluster headache.

Theranica's FDA-cleared, drug-free migraine device gains expanded access, more than doubling coverage to 80 million Americans as young as 8 years old who are diagnosed with migraine.

Satsuma’s STS101 nasal powder becomes the first and only DHE nasal powder for the acute treatment of migraine with or without aura in adults.

A recently published meta-analysis reported that fatty acid supplementation, particularly omega-3, may significantly reduce severity, duration, and frequency of migraine in patients.

The switch from 1 anti-CGRP monoclonal antibody to another led to a significant reduction in monthly headache days, regardless of target mechanism, dose history, or time between treatments.

A recently published phase 1 study revealed that coadministration of intranasal zavegepant with an oral contraceptive did not lead to clinically significant changes in drug exposure.

Although the study reported no evidence linking human leukocyte antigen alleles to migraine, the findings were not replicated, suggesting the HLA system may not be involved in migraine susceptibility.

Findings showed that atogepant 60 mg once daily demonstrated significant improvements in functional outcomes for patients with episodic migraine, compared with placebo, over 12 weeks.

A recent analysis of the PRODROME trial explored the impact of ubrogepant, an FDA-approved acute treatment of migraine with or without aura, on patient-reported outcomes in migraine management.

A recent case-control study suggests that although sleep bruxism may not be directly associated with migraine in patients with temporomandibular disorders, mixed bruxism episodes occur more frequently in those with migraine.

Findings demonstrated that fremanezumab significantly reduced the use of acute headache medications and the frequency of migraine-associated symptoms in patients with episodic migraine compared with placebo.

Erenumab (Aimovig) effectively reduced chronic headaches in a patient with a history of aneurysmal subarachnoid hemorrhage, showcasing the therapeutic potential of CGRP-targeting treatments for post-aSAH headaches.

Findings from a recently published large-scale analysis highlighted the high burden of cognitive impairment among veterans with both migraine and TBI.

New research highlights the significant economic burden of misdiagnosed migraine patients, revealing higher healthcare costs and resource utilization over time compared to those with accurate diagnoses.

Treatment with the Chordate System led to a significantly greater reduction in monthly headache days during the performance assessment period, with a reduction of 3.5 days compared to 1.2 days in the sham group.

Using more than 100,000 claims, the 36-month cumulative risk of acute myocardial infarction and stroke was similar between erenumab and other anti-CGRP mAbs, with minimal residual bias.

Propranolol showed a stronger protective effect against ischemic stroke compared to other beta-blockers, such as metoprolol and timolol, possibly due to its unique pharmacological profile.

Over a 3-month period, galcanezumab treatment reduced definite dizzy days from 17.9 to 6.6, compared to 18.0 to 12.5 in the placebo group